-DOCSTART- -X- O
Cytomegalovirus -X- _ O
( -X- _ O
CMV -X- _ O
) -X- _ O
infection -X- _ O
is -X- _ O
increasingly -X- _ O
recognized -X- _ O
in -X- _ O
critically -X- _ B-Patient
ill -X- _ I-Patient
immunocompetent -X- _ I-Patient
patients. -X- _ I-Patient
Some -X- _ O
studies -X- _ O
have -X- _ O
demonstrated -X- _ O
an -X- _ B-Outcome
association -X- _ I-Outcome
between -X- _ I-Outcome
CMV -X- _ I-Outcome
disease -X- _ I-Outcome
and -X- _ I-Outcome
increased -X- _ I-Outcome
mortality -X- _ I-Outcome
rates -X- _ I-Outcome
, -X- _ I-Outcome
prolonged -X- _ I-Outcome
intensive -X- _ I-Outcome
care -X- _ I-Outcome
unit -X- _ I-Outcome
and -X- _ I-Outcome
hospital -X- _ I-Outcome
length -X- _ I-Outcome
of -X- _ I-Outcome
stay -X- _ I-Outcome
, -X- _ I-Outcome
prolonged -X- _ I-Outcome
mechanical -X- _ I-Outcome
ventilation -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
nosocomial -X- _ I-Outcome
infections. -X- _ I-Outcome
However -X- _ O
, -X- _ O
there -X- _ O
is -X- _ O
a -X- _ O
considerable -X- _ O
controversy -X- _ O
whether -X- _ O
such -X- _ O
association -X- _ O
represents -X- _ O
a -X- _ O
causal -X- _ O
relationship -X- _ O
between -X- _ O
CMV -X- _ B-Intervention
disease -X- _ I-Intervention
and -X- _ O
unfavorable -X- _ O
outcomes -X- _ O
or -X- _ O
just -X- _ O
a -X- _ O
marker -X- _ O
of -X- _ O
the -X- _ O
severity -X- _ O
of -X- _ O
the -X- _ O
critical -X- _ O
illness. -X- _ O
Detection -X- _ O
of -X- _ O
CMV -X- _ O
using -X- _ O
polymerase -X- _ O
chain -X- _ O
reaction -X- _ O
and -X- _ O
CMV -X- _ O
antigenemia -X- _ O
is -X- _ O
the -X- _ O
standard -X- _ O
diagnostic -X- _ O
approach. -X- _ O
CMV -X- _ O
may -X- _ O
have -X- _ O
variety -X- _ O
of -X- _ O
clinical -X- _ O
manifestations -X- _ O
reflecting -X- _ O
the -X- _ O
involvement -X- _ O
of -X- _ O
different -X- _ O
organ -X- _ O
systems. -X- _ O
Treatment -X- _ O
of -X- _ O
CMV -X- _ O
in -X- _ O
critical -X- _ O
care -X- _ O
is -X- _ O
challenging -X- _ O
due -X- _ O
to -X- _ O
diagnostic -X- _ O
challenge -X- _ O
and -X- _ O
drug -X- _ O
toxicity -X- _ O
, -X- _ O
and -X- _ O
building -X- _ O
predictive -X- _ O
model -X- _ O
for -X- _ O
CMV -X- _ B-Intervention
disease -X- _ I-Intervention
in -X- _ O
critical -X- _ O
care -X- _ O
setting -X- _ O
would -X- _ O
be -X- _ O
promising -X- _ O
to -X- _ O
identify -X- _ O
patients -X- _ O
at -X- _ O
risk -X- _ O
and -X- _ O
starting -X- _ O
prophylactic -X- _ O
therapy. -X- _ O
Our -X- _ O
objective -X- _ O
was -X- _ O
to -X- _ O
broadly -X- _ O
review -X- _ O
the -X- _ O
current -X- _ O
literature -X- _ O
on -X- _ O
the -X- _ O
prevalence -X- _ O
and -X- _ O
incidence -X- _ O
, -X- _ O
clinical -X- _ O
manifestations -X- _ O
, -X- _ O
potential -X- _ O
limitations -X- _ O
of -X- _ O
different -X- _ O
diagnostic -X- _ O
modalities -X- _ O
, -X- _ O
prognosis -X- _ O
, -X- _ O
and -X- _ O
therapeutic -X- _ O
options -X- _ O
of -X- _ O
CMV -X- _ B-Intervention
disease -X- _ I-Intervention
in -X- _ O
critically -X- _ O
ill -X- _ O
patients -X- _ O
. -X- _ O

